Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25170259 | 0.99 | KDR (0.39) | KDRPTK6PTK2ADORA3BRD4 | |
| SCHEMBL22123228 | 0.90 | TTK (0.39) | PTK6ADORA3BRD4TTKMAPKAPK5 | |
| Hydrochloric Acid SCHEMBL22123851 | 0.89 | TTK (0.39) | PTK6ADORA3BRD4TTKMAPKAPK5 | |
| SCHEMBL28916287 | 0.88 | ADORA3 (0.39) | PTK6PTK2ADORA3TTK | |
| SCHEMBL22123580 | 0.87 | PTK6 (0.40) | KDRPTK6PTK2ADORA3BRD4 | |
| Hydrochloric Acid SCHEMBL25176076 | 0.87 | KDR (0.40) | KDRPTK6PTK2ADORA3BRD4 | |
| SCHEMBL28961447 | 0.87 | PTK6 (0.51) | PTK6ADORA3 | |
| SCHEMBL30386042 | 0.86 | PTK6 (0.37) | KDRPTK6PTK2ZAP70KARS1 | |
| SCHEMBL28916220 | 0.84 | TTK (0.36) | KDRPTK6BRD4TTKMAPKAPK5 | |
| SCHEMBL25173410 | 0.83 | TTK (0.37) | PTK6BRD4TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916784-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| CN-115485279-A | Antibacterial 8-phenylamino-3- (pyrazol-4-yl) imidazo [1,2-a ] pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-113226469-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-113195496-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195498-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113195497-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-113164771-A | Imidazopyrazine derivatives as antibacterial agents | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020127075-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126952-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020126956-A1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | KDR 3489/4885PTK6 925/4885PTK2 3799/4885 |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | KDR 4560/4885PTK6 1140/4885PTK2 3777/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | KDR 4171/4885PTK6 2141/4885PTK2 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.